Craft

Chiome Bioscience

Stock Price

¥103

2024-10-29

Market Capitalization

¥5.6 B

2024-10-29

Revenue

¥593.3 M

FY, 2025

Chiome Bioscience Summary

Company Summary

Overview
Chiome Bioscience (株式会社カイオム・バイオサイエンス) is a company that researches and develops a drug discovery technology platform. Its proprietary ADLib system is used to generate the monoclonal antibodies for drug discovery research. The company also provides protein expression and purification, stable cell line generation, and Custom Antibody Generation services.
Type
Public
Status
Active
Founded
2005
HQ
Tokyo, JP | view all locations
Website
https://www.chiome.co.jp/?id=en
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Shigeru Kobayashi

    Shigeru Kobayashi, President, Chief Executive Officer

  • Arihiko Bijohira

    Arihiko Bijohira, Executive Director, Chief Financial Officer, Head of Corporate Planning Officer

  • Shose Taoka

    Shose Taoka, Executive Director, Head of Development Division

    • Masamichi Koike

      Masamichi Koike, Executive Director, Head of Research Division

      LocationsView all

      2 locations detected

      • Tokyo, Tōkyō-to HQ

        Japan

        Sumitomo Fudosan Nishi-shinjuku Bldg.No.6, 3-12-1 Honmachi, Shibuya-ku

      • Kawasaki, Kanagawa

        Japan

        1F 2-13-3 Nogawahonmachi, Miyamae-ku

      Chiome Bioscience Financials

      Summary Financials

      Revenue (FY, 2025)
      ¥593.3M
      Gross profit (FY, 2025)
      ¥359.3M
      Net income (FY, 2025)
      (¥982.8M)
      Cash (FY, 2025)
      ¥1.2B
      EBIT (FY, 2025)
      (¥970.0M)
      Enterprise value
      $4.7B

      Footer menu